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Objectives. The present study sought to evaluate the prognostic
value of contractile reserve measured noninvasively during dobut-
amine infusion in patients with severe heart failure.
Background. In patients with severe heart failure there is a
great need for objective criteria to define candidates for heart
transplantation or intensive medical treatment. Cardiac pumping
performance reserve has been shown to have excellent prognostic
value in patients with cardiogenic shock.
Methods. Cardiac peak power, an afterload-independent con-
tractility index, was measured noninvasively at rest and at peak
dobutamine inotropic stimulation. Contractile reserve was de-
fined as the difference between maximal cardiac power at peak
dobutamine dose and baseline value. Maximal cardiac power was
calculated from the maximal product of validated central arterial
pressure and aortic flow.
Results. Results were obtained from 52 subjects (42 patients, 10
control subjects). Twenty-two patients were in New York Heart
Association functional classes III and IV. Of nine patients with a
contractile reserve <1.5 W/ml, eight died during the 3-year
follow-up period. In contrast, all survivors had a contractile
reserve >1.5 W/ml. Using multiple logistic regression analysis,
contractile reserve was shown to be the only predictor of survival.
Conclusions. Contractile reserve measured noninvasively dur-
ing dobutamine infusion is a valuable prognostic indicator in
patients with severe heart failure, with added value to ejection
fraction.
(J Am Coll Cardiol 1997;29:422–8)
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The incidence of congestive heart failure is increasing despite
an observed decline in coronary artery disease mortality (1).
The median survival of patients with severe congestive heart
failure is 2 to 3 years (2). Risk stratification of ambulatory
patients with congestive heart failure is primarily based on
subjective measures, such as clinical and functional assessment
and rest hemodynamic data. The use of exercise tolerance
evaluation provides an objective method for identifying pa-
tients at higher risk for cardiac deaths but cannot be imple-
mented in most patients with severe heart failure who are
unable to exercise. Therefore, although these data are useful in
selecting patients who could potentially benefit from heart
transplantation, they are difficult to obtain in most patients.
Although the success of heart transplantation has stimulated
increasing referrals of patients with heart failure, the number
of donor hearts has not increased significantly during the past
3 years (3). The limited supply of donors and the restricted life
span of donor hearts justify the strategy of postponing trans-
plantation in patients who improve, increasing the need for
objective criteria to define the patients with refractory heart
failure (4). When attempting to evaluate prognosis in conges-
tive heart failure, the clinician is faced with a difficult decision
despite the large number of prognostic variables available
today (5). A surprising lack of concordance exists between
some of these prognostic variables, such as exercise capacity,
functional class and ejection fraction, making the choice
among them extremely difficult.
From 1987 to 1991, Tan (6) showed that the cardiac
pumping performance is better assessed by using a pressure
volume index, such as total cardiac hydraulic power output.
This index had excellent prognostic value in patients with
cardiogenic shock (7). Recently, the pumping ability of the
heart was assessed noninvasively during dobutamine stress
testing. Gorcsan et al. (8) showed a diminished contractile
reserve in patients with severe heart failure. Similar findings
were obtained by using a noninvasive method for measuring
cardiac peak power (9). On the basis of these studies, we
hypothesized that contractile reserve, as reflected by the ability
to increase cardiac peak power during dobutamine infusion,
would be a valuable prognostic indicator of survival. To prove
this hypothesis, we undertook the present study.
Methods
Patients. Fifty-two consecutive subjects of 80 referred to
our outpatient clinic were included in the study (42 patients, 10
control subjects; mean [6SD] age 606 5 years, range 49 to 80;
37 men, 15 women; mean diastolic blood pressure 135 6
10 mm Hg, mean systolic blood pressure 83 6 5 mm Hg).
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Patients were included in the study if they were able to finish
a complete echocardiographic dobutamine stress study, mean-
ing that they did not develop chest pains, arrythmias or
excessive hypotension or hypertension necessitating early dis-
continuation of the study. Patients with a suboptimal echocar-
diographic window were also excluded. Although dobutamine
echocardiography is a standard clinical procedure used rou-
tinely in our practice, we did obtain permission from the ethics
committee of the hospital to conduct the study, and written
informed consent was obtained from all subjects.
After careful anamnestic evaluation, 7 patients were found
to be in New York Heart Association functional class I, 13 in
functional class II, 15 in functional class III and 7 in functional
class IV (Table 1). Ten subjects with atypical chest pain were
included as a control group. Patients were assigned to func-
tional classes by two independent, experienced cardiologists
unaware of the study. There were only two patients in whom
discrepancies were found between the two specialists, and a
third competent cardiologist determined the functional class in
these subjects. No patient had experienced an acute coronary
event in the previous 6 months. All patients included in the
study had a history of ischemic heart disease and had a
documented myocardial infarction. Twenty of 42 patients had
more than one myocardial infarction. All patients with symp-
toms of heart failure were treated with digoxin and diuretic
drugs, and all patients in functional classes II to IV were
treated with 25 mg of captopril two or three times a day in
addition to digoxin and diuretic drugs. Ten additional subjects
referred to our outpatient clinic for atypical chest pain were
included in the study as a control group. In these subjects,
coronary artery disease was excluded by exercise test, exercise
thallium perfusion scan and dobutamine echocardiographic
stress test. All other organic heart conditions were excluded by
Doppler echocardiography. Acute ischemic episodes were
ruled out by looking at regional wall motion abnormalities and
electrocardiographic (ECG) changes during dobutamine infu-
sion. Only patients without new regional motion abnormalities
or other documented ischemic episodes were included in the
study. Therefore, the patients were homogeneous with respect
to lack of active ischemic events.
Dobutamine echocardiography. All patients underwent
dobutamine echocardiography, and left ventricular ejection
fraction and contractile reserve were measured (Table 1). The
dobutamine echocardiography protocol in our laboratory con-
sists of an initial dose of 5 mg/kg body weight per min for 3 min,
10 mg/kg per min for 3 min and increments of 10 mg/kg per min
every 3 min. The maximal dobutamine dose used in our
laboratory is 40 mg/kg per min, and the infusion is discontinued
when the patient achieves 85% of the target heart rate for their
age group or if chest pain, ST segment depression and new
regional wall motion abnormalities develop. If the target heart
rate is not achieved, atropine is not used, and the test is
declared “inconclusive.” Target heart rate was achieved in all
patients included in this study.
The patients were classified into two groups: Group A 5 20
patients in functional classes I and II; Group B5 22 patients in
functional classes III and IV. All patients were followed up for
3 years after inclusion in the study.
Measurement of hemodynamic variables. Measurement of
aortic flow. Aortic velocities were measured by continuous
wave Doppler in the apical five-chamber view. Aortic diameter
was measured in a two-dimensional parasternal long-axis view,
just below the aortic orifice from the inner to inner echo at
rest, only because it is thought to remain constant during
exercise or dobutamine infusion (9). Aortic valve area was also
measured. The following variables were obtained at rest and
during dobutamine infusion: Stroke volume 5 p/4 3 (Aortic
diameter)2 3 Aortic velocity time integral (10) and aortic flow.
Aortic flow was calculated from the velocity time integral times
the valve area divided by ejection time. Doppler measurements
of exercise stroke volume at the aortic orifice have been
previously validated by comparison with thermodilution (10)
and recently by Dahan et al. (11) and Borow et al. (12).
End-diastolic volume was measured by using the established
area–length method.
Central arterial pressure measurement. Central arterial pres-
sure was obtained noninvasively by a newly designed
computer-controlled device (13,14). This device consists of
three components: 1) a sphygmomanometric arm cuff attached
to an air pressure unit; 2) a Doppler transducer attached to the
arm at the antecubital space over the brachial artery; and 3) an
ECG monitoring system.
Noninvasive pressure wave forms are generated by measur-
ing the time delay between the R wave on the ECG and the
onset of brachial artery flow (Doppler) during computer-
controlled upper arm deflation. This delay shortens with falling
cuff pressure, so that a plot of pressure versus time delay yields
the ascending portion of the arterial wave form. These wave
forms were compared with the simultaneous invasive ascend-
ing aortic pressure, and a correlation of r 5 0.98 for systolic
pressure and r 5 0.99 for diastolic pressure were found (15).
Cardiac peak power measurement. Peak power, represent-
ing the maximal product of systolic pressure and flow, occurs
early in ejection and is not significantly affected by afterload.
Recent experimental data (16–18) indicate that cardiac peak
power is a relatively afterload-independent contractility index.
It is obtained from the formula Peak power 5 Maximal
product of (P 3 dV/dT), where P 5 central aortic pressure;
and dV/dT 5 aortic flow, computed from the velocity time
Table 1. Baseline Characteristics of 52 Study Subjects
No. of
Patients CR (W/ml)* LVEF (%)*
Control group 10 11 6 0.7 58 6 3
Patients
FC I 7 10 6 1.0 51 6 4
FC II 13 6.0 6 2.0 40 6 3
FC III 15 3.5 6 1.0 24 6 3
FC IV 7 1.0 6 0.5 21 6 3
*Mean value 6 SD. CR 5 contractile reserve; FC 5 New York Heart
Association functional class; LVEF 5 left ventricular ejection fraction.
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integral times the aortic valve area measured in the apical
five-chamber view by Doppler echocardiography. By aligning
the beginning of the flow with the simultaneously recorded
central aortic pressure, instantaneous power measurements
are made, and maximal power is obtained.
Contractile reserve was defined as the difference between
maximal cardiac power obtained at peak dobutamine dose and
the baseline value.
Statistical methods. All patients were followed up for a
period of 3 years. We asked the following two statistical
questions: 1) When the patients were classified into two
groups—those who survived and those who died—was there
any difference between the two groups with regard to any of
the variables in Table 2? 2) What is the predictive power of any
of the variables in Table 2?
Analysis. Question 1 was addressed by using the Wilcoxon-
Mann-Whitney or the Fisher exact test (according to whether
the variable tested was continuous or categoric). Question 2
was addressed by logistic regression, with survival as the
response variable and the remainder as explanatory variables.
Results
Patients. Results were obtained in 52 of 80 consecutive
subjects referred to the outpatient clinic for dobutamine stress
echocardiography. As previously stated (see Methods), only
those patients able to complete the dobutamine stress test
without developing ischemia, arrhythmias or other serious
adverse effects, with an adequate echocardiographic window
and echocardiograms of good quality for accurate analysis,
were included in the study.
Contractile reserve. On the basis of the dobutamine stress
test results, the patients were classified into those with good
contractile reserve (able to increase peak power by.1.5 W/ml)
and those with poor contractile reserve (unable to increase
peak power by $1.5 W/ml). All 20 patients in group A had
good contractile reserve, whereas 9 of the 22 patients in Group
B had poor contractile reserve. At the end of the 3-year
follow-up period, all 20 patients in Group A were alive,
whereas 8 patients in Group B had died (Table 2). Left
ventricular ejection fraction was similar in the surviving and
nonsurviving patients (Table 3). We found a distinct difference
in contractile reserve between survivors and nonsurvivors
(Table 3). All survivors had good contractile reserve (.1.5
W/ml), whereas all eight patients who died had poor contrac-
tile reserve (,1.5 W/ml). Only one patient with poor contrac-
tile reserve remained alive after 3 years (Fig. 1). Contractile
reserve appeared to be the only variable that differed between
survivors and nonsurvivors. The Wilcoxon-Mann-Whitney two-
tailed test gave the extreme value of 213.5 for testing the null
hypothesis of equality of the two groups. The null hypothesis
was rejected at p 5 0.0004. The estimates of mean contractile
reserve in both groups indicate clearly that this variable is
Figure 1. Prognostic value of contractile reserve (CR) versus left
ventricular ejection fraction (LVEF) in severe heart failure. Horizon-
tal line represents the threshold value of 1.5 W/ml obtained after
receiver operating characteristic curve analysis for contractile reserve.
As shown, eight of nine patients with contractile reserve below the line
died within the follow-up period. All patients with contractile reserve
.1.5 W/ml stayed alive.
Table 2. Characteristics of 22 Patients in Functional Classes III
and IV
Pt No./
Gender Age (yr) CR (W/ml) LVEF (%) Survival
1/M 56 2.9 9 1
2/M 62 2.8 15 1
3/M 68 2.0 33 1
4/M 68 3.5 25 1
5/M 80 1.0 11 1
6/M 56 3.7 19 1
7/M 58 1.9 32 1
8/F 62 4.5 28 1
9/M 63 4.0 22 1
10/M 50 5.0 26 1
11/M 57 8.0 31 1
12/M 51 6.0 35 1
13/M 61 4.8 35 1
14/F 52 4.0 34 1
15/M 51 0.9 26 0
16/M 57 0.9 13 0
17/M 54 1.2 11 0
18/M 49 1.5 11 0
19/M 69 1.5 27 0
20/F 67 0.4 35 0
21/M 60 1.0 30 0
22/M 57 0.3 20 0
F 5 female; M 5 male; Pt 5 patient; 1 5 alive; 0 5 dead; other
abbreviations as in Table 1.
Table 3. Left Ventricular Ejection Fraction and Contractile Reserve
After 3-Year Follow-Up in Survivors and Nonsurvivors
FC I/II FC III/IV
Alive
(n 5 20)
Dead
(n 5 0)
Alive
(n 5 20)
Dead
(n 5 8)
LVEF (%) 47 6 5 22 6 11 25 6 7
CR (W/ml) 10 6 0.4 3.8 6 1* 1 6 0.5
*p 5 0.0004. Data presented are mean value 6 SD. Abbreviations as in
Table 1.
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much higher in survivors (3.85 W/ml) than in nonsurvivors
(0.96 W/ml).
Other hemodynamic variables. The changes in and peak
values of left ventricular ejection fraction, end-diastolic vol-
ume, end-systolic volume, heart rate and blood pressure
elicited by dobutamine were also analyzed but failed to dis-
criminate between survivors and nonsurvivors (Tables 4 to 7).
When left ventricular end-systolic volume and ejection fraction
were compared, we found no significant increase in mortality
in patients with a high end-systolic volume versus those with a
lower end-systolic volume at the same ejection fraction. Stroke
work and rest peak power and change in stroke work and peak
power were found to be the only predictors of survival (Tables
4 to 7). Contractile reserve was found to be the only variable
with predictive power regarding survival. Logistic regression of
the odds of dying versus surviving for a given contractile
reserve yielded the following regression coefficients (standard
error): alpha (intercept)5 5.7665 (3.027); and beta5 23.6442
(2.0117). These coefficients are interpreted as follows: A
patient with a contractile reserve of 0.96 W/ml (mean contrac-
tile reserve among nonsurvivors) is 10 times more likely to die
than to survive. In contrast, a patient with a contractile reserve
of 3.85 W/ml (mean contractile reserve among survivors) is
3,800 times more likely to survive. The likelihood ratio chi-
square statistic for this regression is 20.134 for 1 degree of
freedom, yielding a p value of 0.0001.
Discussion
In the present study we found that left ventricular ejection
fraction at rest and at peak dobutamine dose and the change in
ejection fraction in patients with severe heart failure (function-
al classes III and IV) were not good predictors of survival
(Tables 3 and 4.) Patients who survived the 3-year follow-up
period had a mean left ventricular ejection fraction of 22 6
11%, whereas in those who died, it was 25 6 7% (p 5 NS). In
contrast, contractile reserve was significantly higher in the 14
patients who survived the follow-up period (3.8 6 1 W/ml)
than in those who died (1 W/ml). When multiple regression
logistic analysis was used, contractile reserve was found to be
the only predictor of survival in patients with severe heart
failure. According to the statistical analysis, a patient with a
contractile reserve value of 0.96 W/ml is 10 times more likely to
die within the 3-year period, whereas a patient with contractile
reserve .3.85 W/ml is 3,800 times more likely to survive the
3-year follow-up period.
Previous studies. These findings are similar to those of Tan
and Littler (7). In 28 consecutive patients with clinically
documented cardiogenic shock, cardiac pumping reserve was
evaluated by the response of the failing heart to graded
incremental dobutamine infusion (2.52 to 40 mg/kg per min)
after optimizing the left ventricular preload. Eleven of the
patients survived for .1 year of follow-up. All patients with
cardiac power of ,1 W or a peak left ventricular stroke work
index ,0.25 J/m2 died, whereas all those with higher values
lived .1 year. Tan and Littler (7) concluded their study by
stating that the availability of such a prognostic indicator would
be invaluable for formulating management plans for these
patients. In the present study, stroke work was also predictive
of survival, although cardiac peak power proved to be superior.
Gorcsan et al. (8) developed a noninvasive method for esti-
mating contractile reserve using on-line echocardiographic
measurements for volume and finger photopletismography for
Table 4. Rank Sum Two-Tailed (Mann-Whitney) Test: Survivors
Versus Nonsurvivors
Rest
Value
Peak Value
Minus Baseline
Value (delta)
EDV 0.1502 NA
SV 0.6904 0.0508
LVEF 0.0508 NA
HR 0.0904 0.18
CO 1.0168 0.0508
SVR 0.8114 0.3375
PP 0.0269 0.0004
SW 0.2481 0.0457
CO 5 cardiac output; delta 5 change; EDV 5 end-diastolic volume; HR 5
heart rate; LVEF5 left ventricular ejection fraction; NA5 not applicable; PP5
peak power; SV 5 stroke volume; SVR 5 systemic vascular resistance; SW 5
stroke work.
Table 5. Analysis of Significance and Prognostic Value of End-Diastolic Volume, Stroke Volume, Left Ventricular Ejection Fraction and
Heart Rate Obtained During Dobutamine Infusion*
End-Diastolic Volume Stroke Volume
Left Ventricular Ejection
Fraction Heart Rate
Rest Max Delta Rest Max Delta Rest Max Delta Rest Max Delta
Dead
Average 253.75 234.13 219.63 45.75 47.13 1.38 25% 24% 2% 90.63 120.50 28.88
SD 121.53 98.80 61.05 18.45 15.57 14.93 7% 12% 6% 19.04 24.71 18.42
Alive
Average 195.40 192.10 23.30 54.00 67.91 13.91 22% 40% 9% 80.64 117.73 37.09
SD 71.32 52.59 32.73 26.16 21.28 22.32 11% 16% 15% 15.42 19.78 16.38
p value 0.1502 0.3375 0.5806 0.6904 0.0214 0.0508 0.0508 0.0104 0.1531 0.0904 0.3773 0.18
*By performing repeat multiple post hoc analyses with various subsets of variables not defined as end points at the beginning of the study, a spurious statistical
significance may ensue; therefore, these data should be viewed with caution. Delta 5 change; Max 5 maximal.
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pressure (8). They found that during dobutamine infusion,
there is attenuated contractile reserve in patients with heart
failure. Our findings are similar to theirs. In addition, in a
recent study (9) we found a correlation between severity of
heart failure and contractile reserve.
Present study and possible explanations. Method used.
Analysis of the pressure–volume relation is essential to define
the complex determinants of ventricular performance, includ-
ing preload, afterload and contractile state (19–24). Until
recently, invasive methods were used to measure pressure–
volume indexes. Noninvasive methods of the estimating end-
systolic pressure–volume relation have been described using
echocardiography or nuclear medicine techniques. The diffi-
culty with noninvasively measuring pressure–volume indexes
resides in lack of accurate measurement of volume as well as
central arterial pressure. The method used in the present study
accurately estimates central arterial pressure noninvasively
(13). By multiplying the time velocity integral obtained by
Doppler with the aortic valve area measured by echocardiog-
raphy, a reasonable estimate of stroke volume and aortic flow
can be obtained. This method was recently extensively vali-
dated (10–12). At the beginning of ejection, both the cali-
brated central aortic pressure and aortic flow curve can be
aligned, and a power curve can be calculated. The peak value
of this curve, peak power, is the index used in the present study
to measure contractile reserve. During dobutamine infusion,
little change in end-diastolic volume was observed (9). Thus, in
the same patient, changes in peak power are not substantially
affected by changes in end-diastolic volume. Similar results
were found by using a gamma camera during exercise (25,26).
Thus, although great effort was made to measure accurately
end-diastolic volume, the accuracy of this measurement was
not critical in our opinion for the interpretation of the results.
Recently, Gorcsan at al. (8,27) reported assessment of left
ventricular performance by on-line pressure–area relation
using echocardiographic automated border detection, but they
used the peripheral arterial pressure obtained from a finger
cuff photopletismograph for their calculation, thus allowing for
errors in estimation of pressure-based ventricular perfor-
mance. As shown in previous studies (28,29) the contour of
peripheral arterial pressure is completely different from the
central arterial pressure because of numerous reflections and
summations of peripheral arterial waves. However, when using
pressure–volume area relations and indexes such as stroke
work, the error involved in measurement is reduced, and serial
changes during dobutamine infusion in the same subject may
have an important physiologic message. Indeed, Gorscan et al.
(27) show attenuated contractile reserve in patients with
advanced heart failure.
As shown in previous studies (16–18), cardiac peak power is
a reliable noninvasive afterload-independent index of left
ventricular performance, reflecting changes in contractility.
Table 6. Analysis of Significance and Prognostic Value of Cardiac Output, Stroke Work and End-Systolic Volume Obtained During
Dobutamine Infusion*
Cardiac Output Stroke Work End-Systolic Volume
Rest Max Delta Rest Max Delta Rest Max Delta
Dead
Average 4,131.88 5,464.75 1,332.88 5,569.25 5,485.00 284.25 299.50 281.25 218.25
SD 1,789.90 1,640.63 1,887.34 2,455.50 2,732.92 1,714.41 129.80 101.48 64.25
Alive
Average 4,135.73 7,834.91 3,699.18 6,973.80 9,119.70 2,145.90 249.40 258.60 9.20
SD 1,309.60 2,268.28 2,639.19 3,130.71 3,133.90 2,961.23 79.23 59.18 47.84
p value 1.0168 0.0133 0.0508 0.2481 0.0136 0.0457 0.2908 0.5806 0.3895
*By performing repeat multiple post hoc analyses with various subsets of variables not defined as end points at the beginning of the study, a spurious statistical
significance may ensue; therefore, these data should be viewed with caution. Abbreviations as in Table 5.
Table 7. Analysis of Significance and Prognostic Value of Systolic Blood Pressure, Diastolic Blood Pressure and Mean Arterial Blood
Pressure Obtained During Dobutamine Infusion*
Systolic Blood Pressure Diastolic Blood Pressure Mean Arterial Blood Pressure
Rest Max Delta Rest Max Delta Rest Max Delta
Dead
Average 146.13 134.88 211.25 74.13 72.38 21.75 98.13 93.21 24.92
SD 30.54 41.91 24.42 8.85 11.89 8.15 14.61 21.11 9.26
Alive
Average 157.60 168.20 10.60 79.40 77.30 22.10 105.47 107.60 2.13
SD 22.36 21.17 24.17 10.53 6.57 8.92 13.39 10.48 11.88
p value 0.1252 0.0078 0.0457 0.2111 0.1786 0.7296 0.2111 0.0177 0.1252
*By performing repeat multiple post hoc analyses with various subsets of variables not defined as end points at the beginning of the study, a spurious statistical
significance may ensue; therefore, these data should be viewed with caution. Abbreviations as in Table 5.
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Preload-adjusted maximal power was shown (18) to be an
afterload-independent index very sensitive to inotropic
changes. When compared with the end-systolic pressure–
volume relation (ESPVR slope), there was excellent correla-
tion with linear regression given by the formula
%DEes5 0.91 p%DPWRmx/EDV2 1 5.8 ~r5 0.9, p, 0.001!,
where %DEes 5 percent change in ventricular elastance; and
%DPWRmx/EDV2 5 change in maximal cardiac power nor-
malized by end-diastolic volume. Similar correlations were
obtained when the power index was compared with the slope of
stroke work–end-diastolic volume relation (r 5 0.67, p 5
0.002).
Predictive power of ejection fraction. Rest ejection fraction
measured by gated equilibrium radionuclide angiography has
emerged as an established noninvasive method for accurate
measurement of left ventricular function at rest and to some
extent during exercise. Numerous studies have shown consis-
tently that the severity of left ventricular dysfunction, as
reflected by the reduction in rest ejection fraction, is one of the
most important (if not the most important) determinants of
prognosis in patients after acute myocardial infarction (30,31).
In the present study, when all subjects were evaluated, ejection
fraction was an important prognostic predictor. As shown in
Table 1, all patients who did not survive the study had a low
ejection fraction, whereas all those who had a high ejection
fraction (.40%) survived the follow-up period. However,
when the patients with severe heart failure (functional classes
III and IV) and a markedly reduced left ventricular ejection
fraction were evaluated, the predictive power of left ventricular
ejection fraction was significantly reduced. In fact, there was no
difference in mean left ventricular ejection fraction between
the survivors and nonsurvivors (Table 3). Even when changes
in left ventricular ejection fraction and peak ejection fraction
were considered (Tables 4 to 7), no difference was found
between survivors and nonsurvivors when multivariant logistic
regression analysis was used. Some spurious significances were
found using the Mann-Whitney test with peak ejection frac-
tion, maximal stroke volume, peak systolic blood pressure,
change in blood pressure and maximal mean arterial blood
pressure. As shown in Tables 4 to 7, other variables, such as
end-diastolic volume, end-systolic volume and heart rate did
not succeed in differentiating between survivors and nonsurvi-
vors. In contrast, pressure–volume indexes, such as stroke work
and peak power, had good predictive value, and peak power
reached a statistical significance of p 5 0.0004 (Tables 4 to 7).
It should also be stressed that although left ventricular ejection
fraction has good prognostic value in general, it cannot predict
quality of life in patients with heart failure, and its correlation
with exercise capacity is poor (32).
Contractile reserve. As shown in Figure 1, contractile re-
serve is superior to left ventricular ejection fraction as a
predictor of survival. There are several possible reasons for this
superiority: Contractile reserve measures the pumping ability
of the heart, whereas left ventricular ejection fraction mea-
sures the interaction between the heart and the peripheral
vasculature and as such is a multifactorial index. The direct
dependence of contractile reserve on the amount of available
contracting myocardium (a strong predictor of prognosis)
makes this index much more accurate for predicting prognosis
than left ventricular ejection fraction. In patients with a low left
ventricular ejection fraction, there is a remarkable lack of
correlation between left ventricular ejection fraction, func-
tional class and exercise capacity (33). Ejection fraction, like all
diagnostic indexes, has an optimal range and is less accurate at
the upper and lower ends of the spectrum. At the lower end are
patients with severe heart failure. Pumping ability and contrac-
tile reserve of the heart are critical for everyday physical
activity in these patients. Therefore, these indexes will better
reflect functional class, exercise capacity and survival of these
patients than left ventricular ejection fraction, which is sub-
stantially affected by afterload. Rest ejection fraction is an easy
criterion for screening patients at high risk of dying (e.g., a very
low ejection fraction). Contractile reserve has added value in
this subset of patients identified by ejection fraction and will
further delineate those patients who are more likely to survive.
When ejection fraction was tested for its prognostic value
together with other hemodynamic variables, functional class
emerged as the only significant clinical variable in a multivari-
able analysis (34). Similarly Cohn et al. (33) found functional
class to be a very good prognostic index. In previous work we
showed (9) that contractile reserve has excellent correlation
with functional class (r 5 0.9), and it is therefore logical to
assume that contractile reserve would also have good prognos-
tic ability. Reduction in contractile reserve, especially in severe
heart failure, strongly suggests that the results of the present
study, albeit in a small group of patients, represent a true
phenomenon. In their recent work, Stelken et al (34) empha-
sized that percent achieved of predicted maximal oxygen
consumption provides important prognostic information in
severe heart failure. Patients who achieve .50% predicted
maximal oxygen consumption have an excellent short-term
prognosis when treated medically, and heart transplantation
can be safely deferred. However, most patients with severe
heart failure are unable to exercise, and although the index
proposed by Stelken et al. (34) appears promising, it is limited
to only those patients who are able to exercise. However, our
test, using dobutamine infusion, is easily applicable to all
patients regardless of the severity of their condition. There-
fore, the index that we propose—contractile reserve—is a
noninvasive, easily obtainable index that can be applied to all
patients with heart failure.
Limitations of the study. The study was conducted in a
relatively small, narrowly defined group of patients, and the
results should not be generalized to other patient populations.
Because of the small sample size, the results should be viewed
as clear tendencies rather than very significant findings. How-
ever, the results are unambiguous and clear-cut and warrant, in
our opinion, a larger clinical trial.
The method used in the present study (measurement of
aortic flow by Doppler echocardiography combined with non-
invasively obtained central arterial pressure) was validated in a
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previous study (9). This method assumes that aortic valve area
remains constant during dobutamine infusion and that end-
diastolic volume does not change substantially. We found very
little change in end-diastolic volume during dobutamine infu-
sion. Thus, it is our opinion that changes in end-diastolic
volume do not significantly affect contractile reserve in a
particular patient.
Conclusions. In the present study we showed that contrac-
tile reserve, as measured by dobutamine-induced inotropic
stimulation, is a valuable prognostic indicator for patients with
severe heart failure. Left ventricular ejection fraction remains
an excellent prognostic indicator when screening the general
population. In the subset of patients with a very low ejection
fraction, contractile reserve has additive value by pinpointing
those patients who are at high risk and are candidates for heart
transplantation. This study was performed only in a narrow
subset of patients with ischemic cardiomyopathy without active
ischemia. Therefore, these findings should be confirmed in
patients with dilated cardiomyopathy, ischemic heart disease
with inducible ischemia and valvular heart disease. Further
studies need to be performed to evaluate the strength of this
index in a large number of patients.
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